Intrommune Therapeutics is a clinical stage biotechnology company developing safe and effective options for the >220 million individuals suffering with food allergies across the globe. The company’s platform technology enables daily treatments to be self-administered in a way that integrates seamlessly into a patient’s daily routine. This allows them and their families to live their lives without anxiety and fear of accidental exposure to allergy-triggering foods, which can lead to life-threatening allergic reactions. The company’s Oral Mucosal Immunotherapy (OMIT) platform is based on well-accepted principles of desensitization to specific foods. OMIT optimizes exposure of controlled doses allergenic proteins to a patient’s immune system by embedding them into a specially formulated toothpaste. Thus, self-administration of the therapy occurs simultaneously as a patient brushes their teeth, with no additional effort. Daily use of OMIT can drive the immune system toward tolerance of specific allergy-causing foods - without the need to consume and ingest proteins of those foods.The initial OMIT product in development is INT301 for the treatment of peanut allergy, which has completed a successful Phase 1B study in allergic subjects, demonstrating excellent safety and adherence while also providing indications of efficacy in a difficult-to-treat allergy population. Intrommune is now moving to initiate a Phase 2 study in peanut allergic children. Future OMIT products will address the 9 food allergies (peanut, tree nuts, egg, wheat, milk, soy, shellfish, fin fish, and sesame), individually or in combination, that cause over 90% of food allergy reactions.

Allovate® is a private biopharmaceutical company developing products to address unmet medical needs in clinical management of atopic and allergy-related disorders. The key program of the company is its oral mucosal immunotherapy product platform, Allerdent®, an improved and patient-friendly mode of antigen-specific immunotherapy. The company’s products enable the treatment of respiratory allergies that are provoked by environmental triggers, such as pollen, pet dander, mold, and dust.

Vaxiva Biosciences was a Tokyo-based bioventure that focused on development of vaccine adjuvants to support and expand immunization programs for influenza and other infectious diseases in Japan and other Asian territories.

Kyorin is an established Japanese pharmaceutical company that operates a full-spectrum of capabilities in drug discovery, R&D, clinical development, drug manufacturing, and sales. Kyorin's franchise portfolio encompasses respiratory diseases, CNS disorders, and infectious diseases.

Trillium Medical Ventures is a biotechnology consulting firm that focuses on identifying and evaluating healthcare assets that align with the strategic objectives of large pharmaceutical clients.